Sapvax Enables & Improves the Clinical Potential of Neoantigen Vaccines


Each individual tumor has a unique signature of mutations resulting in the expression of “neoantigens.” Major hurdles remain in rapidly generating effective neoantigen vaccines that will induce tumor clearance. To address this unmet need, SapVax is seeking partners to enhance neoantigen selection technologies with our self-adjuvanting strategy. Based on each patient’s tumor signature, selected neoantigen peptides will be synthesized, covalently linked to the SapVax adjuvant in a single rapid manufacturing step, and injected into the patient to expand killer T cells. These killer T cells can then recognize and kill cancer cells expressing neoantigen peptides for enhanced tumor clearance.

Our discovery stage SVX-NEO program provides a path to more effective anti-tumor neoantigen cancer vaccines.